Clinical-stage gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that positive preclinical data on its lead candidate, Reqorsa Gene Therapy, will be presented at the 2024 EORTC-NCI-AACR Symposium, taking place from 23-25 October 2024 in Barcelona.
The data focuses on Reqorsa's potential as a treatment for Ras inhibitor-resistant lung cancer, mesothelioma and glioblastoma.
Collaborators, including the University of Texas MD Anderson Cancer Center and New York University Langone Health, will showcase studies demonstrating that Reqorsa's TUSC2 gene therapy overcomes resistance in KRAS mutant lung cancer and suppresses tumour growth in mesothelioma and glioblastoma. Two provisional patent applications have been filed based on these findings.
Reqorsa, which uses Genprex's Oncoprex Delivery System, specifically targets cancer cells with the TUSC2 gene, delivering promising preclinical results.
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)